APYX · Insider Trading
Apyx Medical Corporation Common Stock
Every open-market purchase and sale reported by APYX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Lawrence Waldman | Director | MIXED | +6,976 | +$2 |
| 2026-06-17 | Shawn David Roman | Chief Operating Officer | MIXED | +4,467 | −$2 |
| 2026-06-15 | Charles D. Goodwin II | Chief Executive Officer | A | +213,948 deriv. | — |
| 2026-06-15 | Matthew C Hill | Chief Financial Officer | A | +132,066 deriv. | — |
| 2026-06-15 | Shawn David Roman | Chief Operating Officer | A | +88,044 deriv. | — |
| 2026-06-15 | Wendy Lauren Levine | Director | A | +50,000 deriv. | — |
| 2026-06-15 | Moshe Citronowicz | Sr. V.P. of Operations | A | +63,392 deriv. | — |
| 2026-06-15 | Minnie Baylor-Henry | Director | A | +50,000 deriv. | — |
| 2026-06-15 | Stavros G. Vizirgianakis | Director | A | +450,000 | — |
| 2026-06-15 | Lawrence Waldman | Director | A | +50,000 deriv. | — |
| 2026-03-17 | Moshe Citronowicz | Senior Vice President | M | +37,000 | +$66.60K |
| 2026-01-29 | Shawn David Roman | Chief Operating Officer | M | +12,000 | +$21.60K |
| 2025-05-19 | Matthew C Hill | Chief Financial Officer | A | +100,000 deriv. | — |
| 2025-05-19 | Stavros G. Vizirgianakis | Director | A | +128,000 deriv. | — |
| 2025-05-19 | Charles D. Goodwin II | Chief Executive Officer | A | +193,000 deriv. | — |
| 2025-05-19 | Lawrence Waldman | Director | A | +30,000 deriv. | — |
| 2025-05-19 | Moshe Citronowicz | Sr. V.P. of Operations | A | +36,000 deriv. | — |
| 2025-05-19 | Minnie Baylor-Henry | Director | A | +59,000 deriv. | — |
| 2025-05-19 | Wendy Lauren Levine | Director | A | +64,000 deriv. | — |
| 2025-03-03 | Matthew C Hill | Chief Financial Officer | Buy | +6,000 | +$6.78K |
| 2025-01-17 | Stavros G. Vizirgianakis | Director | A | +50,000 deriv. | — |
| 2025-01-17 | Lawrence Waldman | Director | A | +50,000 deriv. | — |
| 2025-01-17 | Matthew C Hill | Chief Financial Officer | A | +50,000 deriv. | — |
| 2025-01-17 | Wendy Lauren Levine | Director | A | +50,000 deriv. | — |
| 2025-01-17 | Charles D. Goodwin II | Chief Executive Officer | A | +50,000 deriv. | — |
| 2025-01-17 | Minnie Baylor-Henry | Director | A | +50,000 deriv. | — |
| 2025-01-17 | Shawn David Roman | Chief Operating Officer | A | +100,000 deriv. | — |
| 2025-01-17 | Moshe Citronowicz | Sr. V.P. of Operations | A | +36,000 deriv. | — |
| 2024-08-13 | Matthew C Hill | Chief Financial Officer | Buy | +5,336 | +$6.03K |
| 2024-08-12 | Wendy Lauren Levine | Director | A | −17,000 deriv. | — |
| 2024-08-12 | Craig A. Swandal | Director | A | −17,000 deriv. | — |
| 2024-08-12 | Lawrence Waldman | Director | A | −17,000 deriv. | — |
| 2024-08-12 | Michael Geraghty | Director | A | −17,000 deriv. | — |
| 2024-08-12 | Minnie Baylor-Henry | Director | A | −17,000 deriv. | — |
| 2024-08-12 | John C. Andres | Director | A | −17,000 deriv. | — |
| 2024-08-12 | Stavros G. Vizirgianakis | Director | A | −17,000 deriv. | — |
| 2024-01-11 | Moshe Citronowicz | Sr. V.P. of Operations | A | +72,000 deriv. | — |
| 2024-01-11 | Charles D. Goodwin II | Chief Executive Officer | A | +243,000 deriv. | — |
| 2024-01-11 | Matthew C Hill | Chief Financial Officer | A | +150,000 deriv. | — |
| 2024-01-11 | Todd Hornsby | Executive Vice President | A | +100,000 deriv. | — |
| 2023-12-14 | Matthew C Hill | Chief Financial Officer | Buy | +2,500 | +$5.47K |
| 2023-11-15 | Charles D. Goodwin II | Chief Executive Officer | Buy | +50,000 | +$78.50K |
| 2023-08-15 | Lawrence Waldman | Director | A | −17,000 deriv. | — |
| 2023-08-15 | Wendy Lauren Levine | Director | A | −17,000 deriv. | — |
| 2023-08-15 | John C. Andres | Director | A | −17,000 deriv. | — |
| 2023-08-15 | Minnie Baylor-Henry | Director | A | −17,000 deriv. | — |
| 2023-08-15 | Craig A. Swandal | Director | A | −17,000 deriv. | — |
| 2023-08-15 | Andrew Makrides | Director | A | −17,000 deriv. | — |
| 2023-08-15 | Michael Geraghty | Director | A | −17,000 deriv. | — |
| 2023-07-19 | Lawrence Waldman | Director | M | +5,338 | +$15.85K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Stavros G. Vizirgianakis | Director | 2,196,191 | $5.69M |
| Moshe Citronowicz | Sr. V.P. of Operations | 493,504 | $1.28M |
| Charles D. Goodwin II | Chief Executive Officer | 90,000 | $233.10K |
| Lawrence Waldman | Director | 49,877 | $129.18K |
| Shawn David Roman | Chief Operating Officer | 16,467 | $42.65K |
| Matthew C Hill | Chief Financial Officer | 8,500 | $22.02K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APYX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.